{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:27:19Z","timestamp":1787171239111,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Research Project of the First Affiliated Hospital of Nankai University","award":["2025YJZD002"],"award-info":[{"award-number":["2025YJZD002"]}]},{"name":"Tianjin Key Specialty Construction Project for combining traditional Chinese and Western medicine","award":["ZDZKKF02"],"award-info":[{"award-number":["ZDZKKF02"]}]},{"name":"Horizontal research fundings","award":["HKRA2025080246, 320.6750.2025-20-31"],"award-info":[{"award-number":["HKRA2025080246, 320.6750.2025-20-31"]}]},{"name":"Hospital horizontal research fundings","award":["2019SHHLMCH, 2024YJ023, 2019ZGJCJJLM, 2024YJ020"],"award-info":[{"award-number":["2019SHHLMCH, 2024YJ023, 2019ZGJCJJLM, 2024YJ020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08781-z","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:09:24Z","timestamp":1786432164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors"],"prefix":"10.1186","volume":"24","author":[{"given":"Fenge","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Lizee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"8781_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1126\/science.adp1130","volume":"385","author":"SA Rosenberg","year":"2024","unstructured":"Rosenberg SA. Lymphocytes as a living drug for cancer. Science. 2024;385:25\u20136. https:\/\/doi.org\/10.1126\/science.adp1130.","journal-title":"Science"},{"key":"8781_CR2","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","volume":"42","author":"AA Sarnaik","year":"2024","unstructured":"Sarnaik AA, Hwu P, Mule JJ, Pilon-Thomas S. Tumor-infiltrating lymphocytes: A new hope. Cancer Cell. 2024;42:1315\u20138. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.015.","journal-title":"Cancer Cell"},{"key":"8781_CR3","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1016\/j.immuni.2024.08.014","volume":"57","author":"J Chiffelle","year":"2024","unstructured":"Chiffelle J, et al. Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity. 2024;57:2466\u2013e248212. https:\/\/doi.org\/10.1016\/j.immuni.2024.08.014.","journal-title":"Immunity"},{"key":"8781_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/d41573-024-00035-1","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. Nat Rev Drug Discov. 2024;23:238. https:\/\/doi.org\/10.1038\/d41573-024-00035-1.","journal-title":"Nat Rev Drug Discov"},{"key":"8781_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/14712598.2022.2072206","volume":"22","author":"A Nowroozi","year":"2022","unstructured":"Nowroozi A, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms. Expert Opin Biol Ther. 2022;22:735\u201345. https:\/\/doi.org\/10.1080\/14712598.2022.2072206.","journal-title":"Expert Opin Biol Ther"},{"key":"8781_CR6","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1158\/1078-0432.CCR-19-3977","volume":"26","author":"R Ferrarotto","year":"2020","unstructured":"Ferrarotto R, et al. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8\u2009+\u2009Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020;26:3211\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3977.","journal-title":"Clin Cancer Res"},{"key":"8781_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18:842\u201359. https:\/\/doi.org\/10.1038\/s41423-020-00565-9.","journal-title":"Cell Mol Immunol"},{"key":"8781_CR8","doi-asserted-by":"publisher","first-page":"e011066","DOI":"10.1136\/jitc-2024-011066","volume":"13","author":"RAM Rossetti","year":"2025","unstructured":"Rossetti RAM, et al. CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion. J Immunother Cancer. 2025;13:e011066. https:\/\/doi.org\/10.1136\/jitc-2024-011066.","journal-title":"J Immunother Cancer"},{"key":"8781_CR9","doi-asserted-by":"publisher","first-page":"e166070","DOI":"10.1172\/JCI166070","volume":"133","author":"B Apollonio","year":"2023","unstructured":"Apollonio B, et al. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. J Clin Invest. 2023;133:e166070. https:\/\/doi.org\/10.1172\/JCI166070.","journal-title":"J Clin Invest"},{"key":"8781_CR10","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-0205","volume":"24","author":"T Kato","year":"2018","unstructured":"Kato T, et al. Cancer-Associated Fibroblasts Affect Intratumoral CD8\u2009+\u2009and FoxP3\u2009+\u2009T Cells Via IL6 in the Tumor Microenvironment. Clin Cancer Res. 2018;24:4820\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0205.","journal-title":"Clin Cancer Res"},{"key":"8781_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1078-0432.CCR-20-0197","volume":"27","author":"C Watermann","year":"2021","unstructured":"Watermann C, et al. Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. Clin Cancer Res. 2021;27:632\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0197.","journal-title":"Clin Cancer Res"},{"key":"8781_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jhep.2019.05.026","volume":"71","author":"G Zhou","year":"2019","unstructured":"Zhou G, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019;71:753\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2019.05.026.","journal-title":"J Hepatol"},{"key":"8781_CR13","doi-asserted-by":"publisher","first-page":"e003750","DOI":"10.1136\/jitc-2021-003750","volume":"10","author":"SM Fix","year":"2022","unstructured":"Fix SM, et al. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-\u03b2 signaling. J Immunother Cancer. 2022;10:e003750. https:\/\/doi.org\/10.1136\/jitc-2021-003750.","journal-title":"J Immunother Cancer"},{"key":"8781_CR14","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida L, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12:3236. https:\/\/doi.org\/10.1038\/s41467-021-23331-5.","journal-title":"Nat Commun"},{"key":"8781_CR15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","volume":"31","author":"JK Jadlowsky","year":"2025","unstructured":"Jadlowsky JK, et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. 2025;31:1134\u201344. https:\/\/doi.org\/10.1038\/s41591-024-03478-6.","journal-title":"Nat Med"},{"key":"8781_CR16","doi-asserted-by":"publisher","unstructured":"Schlabach MR, et al. Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR\/Cas9 screens. J Clin Invest. 2023;133. https:\/\/doi.org\/10.1172\/JCI163096.","DOI":"10.1172\/JCI163096"},{"key":"8781_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccell.2025.03.024","volume":"43","author":"S Mao","year":"2025","unstructured":"Mao S. Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell. Cancer Cell. 2025;43:575\u20136. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.024.","journal-title":"Cancer Cell"},{"key":"8781_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/IJWH.S446768","volume":"16","author":"F Li","year":"2024","unstructured":"Li F, et al. Autologous tumor-infiltrating lymphocyte monotherapy can rapidly shrink tumors in Asian patients with stage III\/IV cervical cancer: two case reports. Int J Womens Health. 2024;16:31\u20139. https:\/\/doi.org\/10.2147\/IJWH.S446768.","journal-title":"Int J Womens Health"},{"key":"8781_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim D, et al. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357\u201360. https:\/\/doi.org\/10.1038\/nmeth.3317.","journal-title":"Nat Methods"},{"key":"8781_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, et al. featureCounts: an efficient general-purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330. https:\/\/doi.org\/10.1093\/bioinformatics\/btt656.","journal-title":"Bioinformatics"},{"key":"8781_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616.","journal-title":"Bioinformatics"},{"issue":"12","key":"8781_CR22","first-page":"879","volume":"12","author":"PD Bos","year":"2012","unstructured":"Bos PD, et al. Patient-derived tumor xenografts in oncology drug development. Nat Rev Cancer. 2012;12(12):879\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"8781_CR23","first-page":"e105","volume":"77","author":"O Shapira","year":"2017","unstructured":"Shapira O, et al. Patient - derived xenografts as an in vivo model to study the tumor microenvironment. Cancer Res. 2017;77(21):e105\u20138.","journal-title":"Cancer Res"},{"issue":"10","key":"8781_CR24","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.4049\/jimmunol.173.10.6312","volume":"173","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, et al. Arginase I production in macrophages allows T-cell suppression and is regulated by the transcription factor NF - kappaB. J Immunol. 2004;173(10):6133\u201340.","journal-title":"J Immunol"},{"issue":"1","key":"8781_CR25","first-page":"a000535","volume":"1","author":"EA Nigg","year":"2009","unstructured":"Nigg EA, et al. Centrosomes and microtubule organization. Cold Spring Harb Perspect Biol. 2009;1(1):a000535.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"8781_CR26","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39:2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612.","journal-title":"J Clin Oncol"},{"key":"8781_CR27","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-018-05032-8","volume":"9","author":"SN Gettinger","year":"2018","unstructured":"Gettinger SN, et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun. 2018;9:3196. https:\/\/doi.org\/10.1038\/s41467-018-05032-8.","journal-title":"Nat Commun"},{"key":"8781_CR28","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1158\/1078-0432.CCR-16-1217","volume":"23","author":"K Ritthipichai","year":"2017","unstructured":"Ritthipichai K, et al. Multifaceted role of BTLA in the control of CD8\u2009+\u2009T-cell fate after antigen encounter. Clin Cancer Res. 2017;23:6151\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1217.","journal-title":"Clin Cancer Res"},{"key":"8781_CR29","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2159-8290.CD-20-0962","volume":"11","author":"MF Sanmamed","year":"2021","unstructured":"Sanmamed MF, et al. A burned-out CD8\u2009+\u2009T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer Discov. 2021;11:1700\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0962.","journal-title":"Cancer Discov"},{"key":"8781_CR30","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1093\/nar\/gkab552","volume":"49","author":"ER Reed","year":"2021","unstructured":"Reed ER, Monti S. Multi-resolution characterization of molecular taxonomies in bulk and single-cell transcriptomics data. Nucleic Acids Res. 2021;49:e98. https:\/\/doi.org\/10.1093\/nar\/gkab552.","journal-title":"Nucleic Acids Res"},{"key":"8781_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","volume":"41","author":"SM Norberg","year":"2023","unstructured":"Norberg SM, Hinrichs CS. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell. 2023;41:58\u201369. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.016.","journal-title":"Cancer Cell"},{"key":"8781_CR32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna S, et al. Stem-like CD8 T cells mediate response to adoptive cell immunotherapy against human cancer. Science. 2020;370:1328\u201334. https:\/\/doi.org\/10.1126\/science.abb9847.","journal-title":"Science"},{"key":"8781_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.immuni.2019.10.014","volume":"51","author":"A Lercher","year":"2019","unstructured":"Lercher A, et al. Type I interferon signaling disrupts the hepatic urea cycle and alters systemic metabolism to suppress T cell function. Immunity. 2019;51:824\u201338. https:\/\/doi.org\/10.1016\/j.immuni.2019.10.014.","journal-title":"Immunity"},{"key":"8781_CR34","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.cmet.2018.04.009","volume":"27","author":"JD Ochocki","year":"2018","unstructured":"Ochocki JD, et al. Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor pyridoxal phosphate depletion and increased polyamine toxicity. Cell Metab. 2018;27:1266\u2013e12806. https:\/\/doi.org\/10.1016\/j.cmet.2018.04.009.","journal-title":"Cell Metab"},{"key":"8781_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41467-024-55420-6","volume":"16","author":"T Kuilman","year":"2025","unstructured":"Kuilman T, et al. Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies. Nat Commun. 2025;16:649. https:\/\/doi.org\/10.1038\/s41467-024-55420-6.","journal-title":"Nat Commun"},{"issue":"4","key":"8781_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"8781_CR37","first-page":"565","volume":"1","author":"L Gattinoni","year":"2015","unstructured":"Gattinoni L, et al. Adoptive immunotherapy for cancer: a review. JAMA Oncol. 2015;1(4):565\u201377.","journal-title":"JAMA Oncol"},{"issue":"10","key":"8781_CR38","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.4049\/jimmunol.173.10.6312","volume":"173","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, et al. Arginase I production in macrophages allows T - cell suppression and is regulated by the transcription factor NF - kappaB. J Immunol. 2004;173(10):6133\u201340.","journal-title":"J Immunol"},{"issue":"8","key":"8781_CR39","first-page":"552","volume":"13","author":"EL Pearce","year":"2013","unstructured":"Pearce EL, et al. Metabolic pathways in T cell activation and differentiation. Nat Rev Immunol. 2013;13(8):552\u201365.","journal-title":"Nat Rev Immunol"},{"issue":"S2","key":"8781_CR40","first-page":"S135","volume":"107","author":"G Wang","year":"2017","unstructured":"Wang G, et al. Arginine metabolism: nitric oxide and beyond. Br J Nutr. 2017;107(S2):S135.","journal-title":"Br J Nutr"},{"key":"8781_CR41","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/cr.2013.127","volume":"23","author":"M Shen","year":"2013","unstructured":"Shen M, et al. Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes. Cell Res. 2013;23:1284\u201395. https:\/\/doi.org\/10.1038\/cr.2013.127.","journal-title":"Cell Res"},{"key":"8781_CR42","doi-asserted-by":"publisher","first-page":"e202404160","DOI":"10.1002\/slct.202404160","volume":"10","author":"MT Islam","year":"2025","unstructured":"Islam MT, et al. Uncovering the Natural Inhibitors From Medicinal Plants to Alleviate Human Cancers Targeting the p53 Protein. Silico Approach ChemistrySelect. 2025;10:e202404160. https:\/\/doi.org\/10.1002\/slct.202404160.","journal-title":"Silico Approach ChemistrySelect"},{"key":"8781_CR43","doi-asserted-by":"publisher","unstructured":"Ahmed, Saif, et al. Pan-cancer analysis of CDC7 in human tumors: Integrative multi-omics insights and discovery of novel marine-based inhibitors through machine learning and computational approaches. Comput Biol Med. 2025;190. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110044.","DOI":"10.1016\/j.compbiomed.2025.110044"},{"key":"8781_CR44","doi-asserted-by":"publisher","first-page":"108718","DOI":"10.1016\/j.compbiolchem.2025.108718","volume":"120","author":"Ayesha","year":"2026","unstructured":"Ayesha, Amin, et al. In silico identification of a prognostic gene signature and virtual screening for hepatocellular carcinoma. Comput Biol Chem. 2026;120:108718. https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108718.","journal-title":"Comput Biol Chem"},{"key":"8781_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00210-019-01629-y","volume":"392","author":"AWK Yeung","year":"2019","unstructured":"Yeung AWK, et al. A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach.Naunyn-Schmiedeberg. \u2018s Arch Pharmacol. 2019;392:393\u2013403. https:\/\/doi.org\/10.1007\/s00210-019-01629-y.","journal-title":"\u2019s Arch Pharmacol"},{"issue":"23","key":"8781_CR46","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.3390\/molecules26237109","volume":"26","author":"P Tagde","year":"2021","unstructured":"Tagde P, et al. The Multifaceted Role of Curcumin in Advanced Nanocurcumin Form in the Treatment and Management of Chronic Disorders. Molecules. 2021;26(23):7109. https:\/\/doi.org\/10.3390\/molecules26237109.","journal-title":"Molecules"},{"issue":"3","key":"8781_CR47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/biom11030392","volume":"11","author":"MT Kabir","year":"2021","unstructured":"Kabir MT, et al. Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers. Biomolecules. 2021;11(3):392. https:\/\/doi.org\/10.3390\/biom11030392.","journal-title":"Biomolecules"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08781-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:09Z","timestamp":1787169729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08781-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8781"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08781-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics committee of Tianjin Beichen Hospital.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient to participate in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of the details of their medical case and any accompanying images.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Y.X. was employed by and F.L. was one of the shareholders of Suzhou Lanma Biotechnology Co.. All the other authors have no conflict of interest to declare.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1068"}}